Beginnings of Personalized Medicine for Myeloma

Ajai Chari, MD

Video Categories: Personalized Medicine

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
July 29, 2015

Improving the Standard of Care

Dr. Jorge Cortes discusses how to improve the current standard of care by better utilizing the drugs and treatments that are already available.

July 13, 2021

Distinctions and Parallels Among TRK Inhibitors

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explore the mutual and contrasting features of TRK inhibitors.